Arrow Bioscience is an immunotherapy startup focused on improving current therapies, creating better ones, and to fulfilling the founding promise of immunotherapy as a monotherapy.
Overview:
We are an immuno-oncology company focused startup on the development and commercialization of novel small molecule therapeutics that serve to enhance the efficacy of antibody immunotherapies. The goal is to maximize the efficiency of the antibody therapies thereby eliminating the deleterious effects of second line and subsequent combinatorial therapies used to overcome resistance. Monoclonal antibody targeted therapy remains the safest and most robust economical treatment plans for patients to date.
Problem and Opportunity:
Targeted therapies using antibodies remain the gold standard for immune based therapies and best approach for patient safety and recovery. However, limitations arise because some patients are innately resistant, others become resistant during treatment. Take for example Follicular non-Hodgkin’s lymphoma, where up to 60% of patients are acutely resistant to anti-CD20, and for patients who relapse approximately 60% of these patients will also become refractory. This is true for every subsequent relapse cycle. To overcome the issue of resistance patients rely on harsher therapies (Chemo/Radiotherapy/Stem Cells/CAR-T) that if effective will expose patients to secondary cancers later in life.
Competitive Advantage:
Our preclinical data reveals a mechanism by which cancer cells become resistant to monoclonal directed therapy. We have characterized this mechanism and can attenuate its signaling with our proprietary small molecule. Inhibiting this signaling mechanism will stabilize the targeted epitope expression, thereby improving antibody efficacy.
